Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharma Q4 Results Preview: Bristol, Allergan, Gilead, GSK, Sanofi, Teva

Executive Summary

Hemophilia and immuno-oncology will be in the spotlight as earnings season continues into February. Will Bristol be a buyer or an acquisition target? How will Sanofi fare with its new acquisitions? And how will Teva and GSK fare as they face generics for top brands?

Advertisement

Related Content

Namenda XR Generics Coming Soon? US Court Rulings Clear Path For Multiple Launches
AbbVie Expects 9% Tax Rate, Thanks To US Tax Reform Law
J.P. Morgan Notebook Day 2: Walmsley On Diversity, Amgen's Overseas Cash, Growing Opdivo, Mylan On US Generic Pricing, Boston's Pipeline And J&J In Alzheimer's
J.P. Morgan Notebook Day 1: Tax Reform At Last, Allergan's Job Cuts, Teva Turnaround, Biogen's Cash, And Getting FDA-Friendly
Allergan Hopes To Add Bipolar Depression To Vraylar's Label
PD-1 Earnings Roundup: Buckle Up For A Bumpy Ride
Bristol's Strong SITC: IDO, 1L Kidney Cancer And New Mechanism Data Bode Well
Bristol's Opdivo Delivers, But CheckMate 227 Uncertainties Cloud Quarter
Gilead Says 16 Cancer Centers Getting Ready To Administer Yescarta
Gilead Offers Split Guidance For HCV; Expects Further Decline In 2017

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100273

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel